Rothwell Figg Secures Path for Client Sandoz in YAZ® Contraceptive Patent Matter

Print PDF Icon
Photo of Rothwell Figg Secures Path for Client Sandoz in YAZ® Contraceptive Patent Matter

The Federal Circuit denied a combined petition for panel rehearing and rehearing en banc brought by Bayer Healthcare Pharmaceuticals Inc. and Bayer Schering Pharma AG – upholding the Court's decision finding that Bayer's patent for its YAZ® contraceptive product was invalid as obvious. The Federal Circuit decision allows Rothwell Figg client Sandoz and other generic manufacturers to continue manufacturing and distributing generic versions of the drug.

Rothwell Figg's Joseph Hynds and Steven Lieberman represented Sandoz in this matter.

Jump to Page

By using this site, you agree to our updated Privacy Policy and our Terms of Use.